Funding for the SNS, BARDA, and IBMSC; promoting safer and more effective treatments in the stockpile; promoting onshoring and domestic manufacturing of medicines and their components; prioritizing investments in more effective treatments to combat AMR; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; FY 26 LHHS appropriations; Rare Pediatric Disease Priority Review Voucher
2025 · 3rd Quarter (July 1 - Sep 30)
BURRELL INTERNATIONAL GROUP LLC (ON BEHALF OF SHIONOGI INC.)
Filed by TRUSYNERGY.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 13, 2025
- Income
- $10,000.00
- Expenses
- Not reported
- Registrant
- TRUSYNERGY
- Filing UUID
- d77eb7f8-6c93-4352-978c-63f0cb4c4d0d
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.